1-9 of 9
Neil P. Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17–Mutant KIT

Available to Purchase
Beth Apsel Winger, Wilian A. Cortopassi, Diego Garrido Ruiz, Lucky Ding, Kibeom Jang, Ariel Leyte-Vidal, Na Zhang, Rosaura Esteve-Puig, Matthew P. Jacobson, Neil P. Shah
Journal: Cancer Research
Cancer Res (2019) 79 (16): 4283–4292.
https://doi.org/10.1158/0008-5472.CAN-18-3139
Published: 15 August 2019
View articletitled, ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17–Mutant KIT
Open the PDF for ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17–Mutant KIT in another window
Includes: Supplementary data
Journal Articles

Abstract NG02: Polyclonal and heterogeneous resistance to targeted therapy in leukemia

Free
Catherine C. Smith, Amy Paguirigan, Chen-Shan Chin, Michael Brown, Wendy Parker, Mark J. Levis, Alexander E. Perl, Kevin Travers, Corynn Kasap, Jerald P. Radich, Susan Branford, Neil P. Shah
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): NG02.
https://doi.org/10.1158/1538-7445.AM2015-NG02
Published: 01 August 2015
View articletitled, Abstract NG02: Polyclonal and heterogeneous resistance to targeted therapy in leukemia
Journal Articles

Abstract 5387: Dual kinase/bromodomain inhibitors for rationally designed polypharmacology

Free
Elizabeth R. Quinn, Pietro Ciceri, Susanne Müller-Knapp, Alison O'Mahony, Oleg Fedorov, Panagis Filippakopoulos, Jeremy P. Hunt, Elisabeth A. Lasater, Gabriel Pallares, Sarah Picaud, Christopher Wells, Lisa M. Wodicka, Neil P. Shah, Stefan Knapp, Daniel K. Treiber
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5387.
https://doi.org/10.1158/1538-7445.AM2014-5387
Published: 01 October 2014
View articletitled, Abstract 5387: Dual kinase/bromodomain inhibitors for rationally designed polypharmacology
Journal Articles

Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro

Free
Elisabeth A. Lasater, Catherine C. Smith, Neil P. Shah
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1893.
https://doi.org/10.1158/1538-7445.AM2012-1893
Published: 15 April 2012
View articletitled, Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro
Journal Articles

Abstract 2923: Phosphoproteomic assessment of CML cells following transient potent inhibition with dasatinib is associated with durable alteration of the STAT5 and RAF/MEK/ERK pathways

Free
Jennifer Gajan, Juan Oses-prieto, Elisabeth A. Lasater, Alma Burlingame, Neil P. Shah
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2923.
https://doi.org/10.1158/1538-7445.AM2011-2923
Published: 15 April 2011
View articletitled, Abstract 2923: Phosphoproteomic assessment of CML cells following transient potent inhibition with dasatinib is associated with durable alteration of the STAT5 and RAF/MEK/ERK pathways
Journal Articles

Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro

Free
Catherine C. Smith, Lauren Damon, Sara Salerno, Neil P. Shah
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4737.
https://doi.org/10.1158/1538-7445.AM2011-4737
Published: 15 April 2011
View articletitled, Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro
Journal Articles

Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations

Available to Purchase
Markus A. Seeliger, Pratistha Ranjitkar, Corynn Kasap, Yibing Shan, David E. Shaw, Neil P. Shah, John Kuriyan, Dustin J. Maly
Journal: Cancer Research
Cancer Res (2009) 69 (6): 2384–2392.
https://doi.org/10.1158/0008-5472.CAN-08-3953
Published: 17 March 2009
View articletitled, Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations
Open the PDF for Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations in another window
Includes: Supplementary data
Journal Articles

Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680

Available to Purchase
Matthew A. Young, Neil P. Shah, Luke H. Chao, Markus Seeliger, Zdravko V. Milanov, William H. Biggs, III, Daniel K. Treiber, Hitesh K. Patel, Patrick P. Zarrinkar, David J. Lockhart, Charles L. Sawyers, John Kuriyan
Journal: Cancer Research
Cancer Res (2006) 66 (2): 1007–1014.
https://doi.org/10.1158/0008-5472.CAN-05-2788
Published: 19 January 2006
View articletitled, Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680
Open the PDF for Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680 in another window
Journal Articles

BMS-354825 is a novel orally bioavailable small molecule ABL tyrosine kinase inhibitor that successfully and safely inhibits the kinase activity of multiple imatinib-resistant BCR-ABL isoforms in vitro and in vivo

Free
Neil P. Shah, Chris Tran, Francis Y. Lee, Charles L. Sawyers
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1299.
Published: 01 April 2004
View articletitled, BMS-354825 is a novel orally bioavailable small molecule ABL tyrosine kinase inhibitor that successfully and safely inhibits the kinase activity of multiple imatinib-resistant BCR-ABL isoforms in vitro and in vivo